Charles River Laboratories Issues 2026 Non-GAAP EPS Guidance Amid Cost-Saving Initiatives
Charles River Laboratories (CRL) has provided financial guidance for 2026, projecting non-GAAP earnings per share (EPS) in the range of $11.35 to $11.55. This outlook comes as the company executes its 'Create the Future' strategy, which aims to achieve more than $300 million in savings through operational improvements. CEO Birgit Girshick noted that the third quarter demonstrated momentum driven by an improving demand environment within the biopharmaceutical sector. The company is currently focused on its 'Pathway to Purpose' initiative, which emphasizes simplifying organizational structures and accelerating investment in high-growth areas to drive long-term efficiency.
Tickers: $CRL
Topics: biopharmaceutical demand corporate restructuring earnings call